Real‐world 52‐week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index
The Journal of Dermatology · 2025-04 · 52 (4) · 663-671
DOI: 10.1111/1346-8138.17617 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 28.01.2025. Verfasst von Teppei Hagino und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Psoriasis, Protein Kinase Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Deucravacitinib, an oral tyrosine kinase 2 inhibitor, is effective for psoriasis. However, long‐term real‐world effectiveness stratified by age and body mass index (BMI) has not been precisely examined. This study aimed to evaluate 52‐week real‐world effectiveness of deucravacitinib in psoriasis patients, stratified by age (≥65 years vs
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Fujimoto Dermatology Clinic, Funabashi, Japan.
ORCID-Profile: Teppei Hagino, Hidehisa Saeki, Naoko Kanda
Zitieren
APA
Hagino, T., Onda, M., Saeki, H., Fujimoto, E., & Kanda, N. (2025). Real‐world 52‐week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index. The Journal of Dermatology, 52(4), 663-671. https://doi.org/10.1111/1346-8138.17617
Vancouver
Hagino T, Onda M, Saeki H, Fujimoto E, Kanda N. Real‐world 52‐week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index. The Journal of Dermatology. 2025;52(4):663-671. doi:10.1111/1346-8138.17617
BibTeX
@article{Hagino2025,
author = {Hagino, Teppei and Onda, Marina and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
title = {Real‐world 52‐week effectiveness of deucravacitinib in psoriasis: A stratified analysis by age and body mass index},
journal = {The Journal of Dermatology},
year = {2025},
volume = {52},
number = {4},
pages = {663--671},
doi = {10.1111/1346-8138.17617}
}
EUVIMED